Akeem Gardner is the Founder and CEO of Canurta. In 2018 Akeem acquired an Industrial Hemp License from Health Canada and began to farm hemp as he embarked on his entrepreneurial venture, which allowed him to meet with the University of Guelph professors in the summer of 2019 to begin the cannflavin project.

At CannMed 23, he will present “Targeting Glioblastoma Invasion and Survival with Cannabis-Derived Flavonoids”. During our conversation, Akeem provides a preview of that presentation, and insights into the following topics:

What are flavonoids and how are they different from cannabinoids and terpenes
The flavonoids that are unique to cannabis, also known as cannflavins
Why cannflavins are not as well-studies as other cannabis compounds
How Akeem became interested in cannflavins
Cantura’s method for isolating, capturing, and concentrating these molecules
Potential medical applications for cannflavins and how they may work in combination with cannabinoids
Thanks to This Episode’s Sponsor: Canurta

Canurta is a preclinical biotechnology company pioneering the discovery and production of novel, polyphenol-rich ingredients to improve chronic disease prevention and recovery. Their research and technology unlocks the significant anti-inflammatory, anti-viral, anti-cancer and neuroprotective potential of plant polyphenols. Canurta aspires to improve health outcomes, promote longevity and pull humans and animals out of the cycle of chronic disease.

To learn more visit canurta.com

Additional Resources

Interference of neuronal TrkB signaling by the cannabis-derived flavonoids cannflavins A and B - https://www.sciencedirect.com/science/article/pii/S2667031323000064
Akeem Gardner on LinkedIn - https://www.linkedin.com/in/akeemgardner/
Request an Invitation to CannMed 23 - https://share.hsforms.com/1205hgIeOTtKRIkwQSRER5A20xr2
Review the Podcast! - https://podcasts.apple.com/us/podcast/cannmed-coffee-talk/id1504218804
CannMed Archive - https://cannmedevents.com/cannmed-video-archives/